Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, Reduces Physical and Behavioral Effects of Morphine Withdrawal
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
(1) Background: Recent data indicate that receptors for GLP-1 peptide are involved in the activity of the mesolimbic system. Thus, the purpose of the present study was to examine the effect of the selective dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, on morphine dependence in mice. (2) Methods: Morphine dependence in mice was obtained by administration of increasing doses of morphine for eight consecutive days, twice a day. On the 9th day of the experiment, the naloxone-induced (2 mg/kg, ip) morphine withdrawal signs (jumping) were assessed. Moreover, behavioral effects of short-term (60 h after morphine discontinuation) and long-term (14 days after morphine discontinuation) morphine withdrawal were observed. In terms of behavioral effects, the depressive effect in the forced swim test and anxiety in the elevated plus maze test were investigated. Locomotor activity of mice was also studied. (3) Results: The administration of linagliptin (10 and 20 mg/kg, ip) for 8 consecutive days before morphine injections significantly diminished the number of naloxone-induced morphine withdrawal signs (jumping) in mice. In addition, the cessation of morphine administration induced depressive behavior in mice which were observed during short- and long-term morphine withdrawal. Linagliptin administered during morphine withdrawal significantly reduced the depressive behavior in studied mice. Furthermore, the short-term morphine withdrawal evoked anxiety which also was reduced by linagliptin in mice. (4) Conclusions: The present study reveals that GLP-1 receptors are involved in morphine dependence. What is more, linagliptin might be a valuable drug in attenuating the physical symptoms of morphine dependence. It might be also a useful drug in reducing emotional disturbances which may develop during the morphine withdrawal period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“It is conjectured, thus, that some gastrointestinal disturbances could appear in mice after administration of higher doses of linagliptin and it could affect the results of the experiments [71].”
ResultSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Opioids excite dopamine neurons by hyperpolarization of local interneurons
Johnson, S., & North, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00483.1992 · Cited by 1,637 · cited 1×
“It also induces the feeling of euphoria [29,30].”
BackgroundNeuroinflammation and depression: A review
Troubat, R., Barone, P., Leman, S., Desmidt, T., Cressant, A., Atanasova, B., Brizard, B., El Hage, W., Surget, A., Belzung, C., et al. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14720 · Cited by 1,107
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 7×
“They also documented that there was direct neuronal GLP-1 signaling from the nucleus solitarius into the VTA and nucleus accumbens.”
BackgroundInfluentialGLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“Experimental data reveal that GLP-1 receptors do not occur only in pancreas [4], but also in the heart [5], kidney [6] and brain [7–9].”
BackgroundLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450 · cited 1×
“Experimental data reveal that GLP-1 receptors do not occur only in pancreas [4], but also in the heart [5], kidney [6] and brain [7–9].”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“This was demonstrated in hippocampal neurons wherein calcium response to glutamate and membrane depolarization was attenuated by GLP-1 peptide, thus, glutamate-induced neurotoxicity and neuroinflammation could be reduced by GLP-1 analogs [57,58].”
BackgroundGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Rinaman, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.059 · Cited by 311
Fiksdal, A., Hanlin, L., Kuras, Y., Gianferante, D., Chen, X., Thoma, M. V., & Rohleder, N. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.11.035 · Cited by 258
Preproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194
Anderberg, R. H., Richard, J. E., Hansson, C., Nissbrandt, H., Bergquist, F., & Skibicka, K. P. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.11.021 · Cited by 170
The gut microbiome and mental health: implications for anxiety- and trauma-related disorders
Malan-Muller, S., Valles-Colomer, M., Raes, J., Lowry, C. A., Seedat, S., & Hemmings, S. M. J. (2018) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2017.0077 · Cited by 161
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127 · cited 1×
“Furthermore, it is known that GLP-1 receptors are located on GABAergic neurons, in the nucleus tractus solitarius [62] and in other brain areas [12,63,64], including the amygdala [12], and that their stimulation leads to GABA release [65].”
BackgroundKorol, S. V., Jin, Z., Babateen, O., & Birnir, B. (2015) · Diabetes · doi:10.2337/db14-0668 · Cited by 101 · cited 1×
“This effect was also demonstrated in the hippocampal CA3 pyramidal neurons of rats wherein stimulation of the GLP-1 receptors increased GABA release from the presynaptic membrane and intensified GABAergic signalization [66].”
BackgroundZhang, Y., Kahng, M. W., Elkind, J. A., Weir, V. R., Hernandez, N. S., Stein, L. M., & Schmidt, H. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0531-4 · Cited by 92 · cited 1×
“For example, the effect of exendin-4, a GLP-1 receptor agonist, reduced oxycodone-taking and -seeking behaviors and did not produce adverse feeding effects in rats [38].”
BackgroundBartlett, A. A., Singh, R., & Hunter, R. G. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-53889-1_8 · Cited by 91
Farkas, I., Vastagh, C., Farkas, E., Bálint, F., Skrapits, K., Hrabovszky, E., Fekete, C., & Liposits, Z. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00214 · Cited by 79
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., & Fedele, E. (2018) · BioFactors · doi:10.1002/biof.1406 · Cited by 46
GLP-1 neurons form a local synaptic circuit within the rodent nucleus of the solitary tract
Card, J. P., Johnson, A. L., Llewellyn‐Smith, I. J., Zheng, H., Anand, R., Brierley, D. I., Trapp, S., & Rinaman, L. (2018) · Journal of Comparative Neurology · doi:10.1002/cne.24482 · Cited by 38
Cited by
Effects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
“Preclinical data suggest that GLP-1 can attenuate withdrawal, as experiments with GLP-1 agonists reduced withdrawal-induced anxiety in rodents (31, 32).”
BackgroundChiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2718 · Cited by 72
“Rather, studies suggest that some of the comparison medications including insulin, metformin, and other GLP-1RAs have bene fi cial effects on reducing nicotine ’ s rewarding effects in both rodents and in human smokers (29 – 35).”
Endogenous opiates and behavior: 2022
Bodnar, R. J. (2023) · Peptides · doi:10.1016/j.peptides.2023.171095 · Cited by 13
Metadata
- Authors
- Listos, J., Listos, P., Baranowska-Bosiacka, I., Karpiuk, A., Filarowska, J., Łupina, M., Słowik, T., Zawiślak, S., & Kotlińska, J.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-04-12
- Volume
- 27
- Issue
- 8
- Pages
- 2478
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4224307902
- Cited by
- 20
- References
- 24
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.